New antibody drug aims to block Brain-Attacking autoantibodies
Disease control
Recruiting now
This Phase 2a trial tests a drug called ART5803 in 30 adults with anti-NMDAR encephalitis or related psychiatric disease. The drug is a lab-made antibody designed to block harmful autoantibodies from attacking brain receptors. The study focuses on safety and tolerability, with ea…
Phase: PHASE2 • Sponsor: Arialys Australia Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC